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SALL1 has been identified as one of four human homologues of the Drosophila region-specific homeotic gene spalt (sal), encoding zinc finger
proteins of characteristic structure. Mutations of SALL1 on chromosome 16q12.1 cause Townes–Brocks syndrome (TBS, OMIM 107480). We
have shown previously that SALL1 acts as a strong transcriptional repressor in mammalian cells when fused to a heterologous DNA-binding
domain. Here, we report that SALL1 contains two repression domains, one located at the extreme N-terminus of the protein and the other in the
central region. SALL1 fragments with the central repression domain exhibited a punctate nuclear distribution pattern at pericentromeric
heterochromatin foci in murine NIH-3T3 cells, suggesting an association between repression and heterochromatin localization. The implications
of these findings for the pathogenesis of Townes–Brocks syndrome are discussed.
© 2005 Elsevier B.V. All rights reserved.Keywords: SALL1; Townes–Brocks syndrome; Transcriptional repression; Repression domain; Heterochromatin1. Introduction
SALL1 belongs to the spalt (sal)-like gene family. Spalt-like
genes regulate developmental processes in many organisms.
Mutations in human SALL1 result in Townes–Brocks syndrome
(TBS; OMIM 107480), an autosomal dominantly inherited
malformation syndrome [1]. TBS is characterized by anorectal
abnormalities (imperforate anus, anal stenosis), abnormalities of
the hands (preaxial polydactyly, triphalangeal thumbs) and feet,
and deformities of the outer ear, often with preauricular tags.
Hearing loss and renal malformations are commonly found,
whereas cardiac defects and mental retardation occur with lower
frequencies. The penetrance of TBS seems to be complete [2].
Our detection rate of SALL1 mutations among typical TBS
patients is about 64% [3].
Mutations in SALL1 have been postulated to cause TBS by
haploinsufficiency. However, a mouse model carrying a Sall1-⁎ Corresponding author. Tel.: +49 761 270 7050; fax: +49 761 270 7041.
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doi:10.1016/j.bbadis.2005.12.005null allele did not exhibit a TBS-like phenotype. The
heterozygous knock-out mice were phenotypically normal,
whereas homozygous Sall1-deficient mice died perinatally from
renal failure caused by severe renal dysplasia or complete renal
agenesis, indicating that Sall1 has an essential role in kidney
development [4]. Instead, a mouse model carrying a mutant
allele designed to mimic a human TBS mutation mostly
recapitulated the TBS phenotype [5]. These data support a
model for the pathogenesis of TBS in which expression of a
truncated SALL1 protein causes abnormal development, either
in a dominant-negative or gain-of-function fashion.
First hints towards an understanding of SALL1 function
were obtained by demonstrating that a GFP-SALL1 fusion
protein localizes to chromocenters and smaller heterochromatin
foci in transiently transfected NIH-3T3 cells [6]. Chromocenters
consist of clustered pericentromeric heterochromatin and
contain telomere sequences. In a yeast two-hybrid screen
PIN2, an isoform of telomere-repeat-binding factor 1 (TRF1),
was identified as an interaction partner of SALL1. Further
SALL1 interacting proteins revealed by this screen were
Ubiquitin-conjugating enzyme 2I, the human homologue of
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an in vitro assay, it was demonstrated that SALL1 is covalently
modified by SUMO-1 in the presence of UBA2/AOS1 and
UBE2I [7].
Since SAL and SAL-like proteins contain multiple possibly
DNA-binding zinc finger motifs, they are postulated to be
transcriptional regulators. Little is known about the direct target
genes regulated by SAL and SAL-like proteins, but we could
indeed show that SALL1 acts as a strong transcriptional
repressor in mammalian cells [6]. For this purpose we linked
SALL1 to a GAL4 DNA-binding domain (GAL4-DB) and
measured the activity of a luciferase reporter gene containing a
GAL4-binding site upstream of its promotor. Using similar
assay systems, two groups reported that the homologous genes
in mouse (Sall1) and chick (csal1) are also potent transcriptional
repressors [8,9]. On the other hand, new results achieved with a
Wnt responsive reporter suggest that murine Sall1 activates the
canonical Wnt signaling pathway [10]. In concordance with
this, an interaction of β-catenin and Sall1 was demonstrated.
Furthermore, there is evidence from chick csal1 that both FGF
and Wnt signals are required for the regulation of csal1
expression in the limb [11]. In ovarian carcinoma-derived cells
and in human ovarian surface epithelial cells, p150 (SALL2)Fig. 1. (A)Diagram of full-length SALL1 and of the twelve SALL1 deletionmutants us
zinc fingers (white) and of the single zinc fingers (black) are depicted as ovals. The SA
domain (GAL4DB). The names of the mutants and their number (written in latin capit
contained in the fragment are put in brackets. The position of the putative N-terminal
central SALL1 fragments revealing repression properties and heterochromatin asso
constructs. (C) Diagram of the repression activity of full-length SALL1 and of the t
normalized luciferase activity of NIH-3T3 cells expressing GAL4DB alone by the
deviation of triplicate transfections from three independent experiments. They demon
terminus and one in the central region.was shown to be a transcriptional activator of the cyclin-Cdk
inhibitor p21, a key factor in G1 checkpoint control [12].
In the study presented here, the repression and heterochro-
matin localization properties of human SALL1 are analyzed in
detail.
2. Material and methods
2.1. Plasmids
The cloning of various cDNA fragments of SALL1 into pBluescript and of
the full-length SALL1 cDNA into pEGFP-C1 (CLONTECH) as well as the
generation of the reporter plasmid pGAL45tkLUC has been described
previously [6,13]. The constructs I–X (see Fig. 1A) were generated by PCR
(constructs III, VI, VII, VIII, XIV–XVI) or by restriction enzyme digestion
(constructs I, II, IV, V, IX, X) and subcloning into pM1 (CLONTECH), a
mammalian vector used for expression of hybrid proteins with the DNA-binding
domain of GAL4. The correct insertion was confirmed by sequencing the
cloning site and the entire ORF.
2.2. Transcription repression assay
NIH-3T3 cells (1.4×105 cells/35 mm plate) were transfected with Roti®-
Fect (ROTH). Each transfection assay was performed in triplicate and included
(i) 0.5 μg of the pM1-SALL1 deletion construct, (ii) 0.5 μg of the pGAL45tkLUCed in this study. TheORF of SALL1 is shown as a box. The positions of the double
LL1 fragments were expressed as fusion proteins with the GAL4-DNA-binding
als) are indicated on the left side. The number of the first and last amino acid (aa)
repression domain is shown as a box, as well as the region of overlap of the three
ciation. (B) Percentage of nuclei with punctate heterochromatin localization of
welve SALL1 deletion mutants. Fold repression was calculated by dividing the
activity of the SALL1 fusion protein. Values are plotted as the mean±standard
strate that SALL1 contains two strong repression domains: one at the extreme N-
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luciferase. Forty-eight hours after transfection, cells were harvested, lysed in 100
μl of lysis buffer (100 mM KH2PO4 pH 7.8, 0.2% (v/v) Triton X-100, 0.5 mM
DTT) and assayed for luciferase and Renilla luciferase activity with an
Autolumat LB953 (Berthold, Wildbad, Germany) as described [14]. All assays
were repeated three times. The median of the repression activity and the standard
deviation were calculated.
2.3. Indirect fluorescence microscopy
NIH-3T3 cells transiently transfected with pM1-SALL1 deletion constructs
were used for indirect immunofluorescence with antibodies against the GAL4-
DNA binding domain (Santa Cruz Biotechnology, sc-510). 48 hours after
transfection, cells were fixed using 2% paraformaldehyde, washed, permeabi-
lized in ice-cold 0.1% Triton-X and blocked in 10% goat serum. Then, the cells
were incubated with the primary antibody, washed and detected with an anti-
goat FITC-conjugated secondary antibody. Images were scored and recorded
with an inverted epifluorescence microscope (Zeiss Axiovert) and a CCD
camera using the appropriate filter settings. Nuclei were counterstained with
1ug/ml DAPI dye (Sigma), and coverslips were mounted using VECTASHIELD
antifade (Vector laboratories).
For each construct, 150 GAL4-DB-positive cells on three coverslips (50 on
each coverslip) from at least two independent transfections were scored for the
pattern of nuclear staining (punctate or diffuse, see text).3. Results and discussion
A reporter gene assay was used to analyze the ability of
human SALL1 to affect transcription. A series of transient
transfections of NIH-3T3 cells was performed with full-length
SALL1 or fragments of SALL1 fused to the GAL4-DNA-
binding domain (see Fig. 1A). The construct pGAL45tkLUC,
which contains the luciferase gene under the control of a
thymidine kinase promotor with a GAL4 binding site, served as
a reporter plasmid. Our assay system was able to detect both
transcriptional activation and repression (data not shown).
We knew from previous experiments [6] that full-length
SALL1 (construct I) strongly represses luciferase expression in
this system. To map the domains responsible for transcriptional
repression twelve partially overlapping deletion mutants of
SALL1 (constructs II–XVI) were used in the reporter gene
assay. In these experiments it became apparent that SALL1
contains two repression domains, one located at the extreme N-
terminus of the protein and the other one in the central region.
3.1. Repression by the N-terminus of SALL1
The construct expressing the first 183 amino acids of SALL1
(construct II) had a strong repression activity and was capable of
repressing transcription about 5-fold (see Fig. 1C). In the final
series of experiments depicted here the full-length SALL1
(construct I) exhibited a weaker repression activity than this
truncated protein. In more than a dozen experiments performed
previously with a slightly different protocol (in which the vector
pCMV-β-GAL was co-transfected to normalize transfection
efficiency) constructs I and II consistently showed similar
repression activities. Removing aa 1–87 of SALL1 from the
deletion construct II (resulting in construct III) completely
abolished repression, suggesting that the 87 N-terminal amino
acids of SALL1 contain a strong repression domain (see Fig. 1).These results correspond well with published data from
murine Sall1: in a similar reporter gene assay, deletion of aa 1–
77 of Sall1 reduced the ability to repress transcription to 10%.
Deletion of aa 1–129 removed all of the repression activity of
Sall1 [8]. The homology between human SALL1 and mouse
Sall1 is 89.9% for the entire protein and reaches 97.4% for the
first 77 amino acids while dropping to only 64.7% in the region
from amino acid 78 to 129. Since the function of SALL1 as a
transcriptional repressor has obviously been conserved in
evolution, this suggests that the repression domain is located
in the highly conserved N-terminus of the protein (amino acids
1–87). This assumption is further supported by the lack of
transcriptional repression mediated by construct III expressing
aa 87–183 of SALL1 in fusion with the GAL4-DB.
Within the region required for repression, all known
vertebrate SAL-like proteins contain a highly conserved single
zinc finger domain of the C2HC-type [15–24]. Such C2HC zinc
finger domains have been postulated to mediate protein–protein
interactions rather than DNA binding (reviewed in [25]). For
murine Sall1 it has been demonstrated that the first 76 amino
acids are required for binding histone deacetylase (HDAC)
repression complex proteins (HDAC1, HDAC2, RbAp46/48,
MTA1, MTA2). Surprisingly, mutation of the C2HC zinc finger
did not affect repression or interaction with the repression
complex [5].
3.2. Repression by the central domain of SALL1
Our data also show that SALL1 contains a second repression
domain: Constructs IV, V, and VI, which do not contain the
extreme N-terminus of SALL1, encode for SALL1 fragments
that exhibited a strong (3- to 4-fold) ability to repress luciferase
expression (see Fig. 1C). The overlap of these SALL1
fragments encompasses aa 434 to aa 690, suggesting that the
central repression domain is located within this part of the
protein. Surprisingly, a construct expressing this overlapping
region (construct XV) had no detectable repression activity, and
the same was observed for six additional SALL1 deletion
mutants in which C-terminal or N-terminal parts of the
repressing SALL1 fragments were systematically removed
(encoded by constructs VII–X and XIV–XVI).
A consistent interpretation for this observation would be that
the repression properties of the central repression domain
depend on a tertiary protein structure which is intact in construct
VI (the smallest repressing fragment from the central region)
and disturbed by any further deletion. Repression apparently
does not depend on the highly conserved second double zinc
finger and the associated single zinc finger in construct VI, since
construct V is able to repress without them. One might speculate
that the first C2H2 double zinc finger is necessary for repression,
since this zinc finger is present in all three central fragments
with repression activity. On the other hand, this double zinc
finger would clearly not be sufficient for repression, since
regions C-terminal and/or N-terminal of the zinc finger are
needed for repression. Possibly two or more sequence elements
in the critical region mediate repression, and their effective
cooperation depends on the correct conformation of the protein.
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contribute to resolving the issue of structural requirements for
the repression function of this region.
A detailed investigation of the central repression domain of
murine Sall1 has not been performed so far, but the existence of
a second repression domain has been reported: A Sall1 fragment
covering aa 436 to 1103 clearly repressed luciferase expression
in a comparable reporter gene assay [8]. In contrast to the N-
terminal repression domain, this central repression domain was
not dependent on HDAC activity.
3.3. Mapping of the heterochromatin localization domain
We used an anti-GAL4-DNA-binding-domain antibody to
visualize the intranuclear localization of all SALL1 fragments
tested in the reporter gene assay by epifluorescence microscopy.
These fusion proteins were transported into the nucleus due to a
nuclear localization signal (NLS) contained in the yeast GAL4-
DNA-binding domain. Hence, this strategy should enable a
mapping of the heterochromatin localization domain in NIH-
3T3 cells independent from an intact native NLS. NIH-3T3
mouse fibroblasts contain easily detectable DAPI-bright regions
of the nucleus which are known to represent pericentromeric
heterochromatin [6].
Only constructs I, IV, Vand VI displayed the typical punctate
distribution at the chromocenters in 45% (construct I, full-
length SALL1), 10% (construct IV), 15% (construct V) and
20% (construct VI) of nuclei (Fig. 2A–D). The other nineFig. 2. Epifluorescence images showing nuclei expressing GAL4DB-SALL1 (A) an
(right pictures). The proteins were detected with primary antibodies against the G
(construct I) and its deletion mutants IV, V, and VI (A–D) in distinct aggregate
heterochromatin [6]. The other nine deletion mutants showed a diffuse nuclear distri
depicted in panel E, which was transfected with construct II.deletion mutants showed a diffuse nuclear distribution including
construct II, which harbors the N-terminal repression domain
(Fig. 2E). It should be noted that due to technical limitations
(i.e. indirect immunofluorescence on transiently transfected
cells) the percentage of nuclei with punctate pattern is probably
an underestimate. When a GFP-SALL1 construct was used
nearly 100% of transfected nuclei exhibited a chromocenter
associated staining pattern [6].
A consistent explanation for these findings will have to refer
to the conformational and/or structural hypothesis discussed
above for the central repression domain, i.e. smaller deletion
mutants (constructs VII to XVI) may lack the correct tertiary
structure and/or additional sequence elements required for
heterochromatin binding. Nevertheless our data suggest that
there is an association between repression by the central domain
and heterochromatin localization, since the three SALL1
deletion mutants with a partially heterochromatic localization
were those who also exhibited a detectable repression activity.
This suggests that the repression properties of the central SALL1
fragments might depend on heterochromatin localization.
The published data on the intracellular localization of murine
Sall1 fragments are limited and support the complex picture
emerging from our observations: A deletion mutant covering aa
1–435 of Sall1 displayed a diffuse nuclear distribution in NIH-
3T3 cells, a fragment from aa 1 to 598 (which included the first
double zinc finger) showed a punctate heterochromatin locali-
zation. A third fragment containing the C-terminal half of Sall1
(aa 599–1324, including double zinc fingers 3, 4 and 5) formedd -SALL1 deletion mutants (B–E) as well as the corresponding DAPI staining
AL4-DNA binding domain. Note the punctate distribution pattern of SALL1
s which correspond to the DAPI-bright regions representing pericentromeric
bution (data not shown). An example for this distribution pattern is the nucleus
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concordance with our results, a predominantly punctate nuclear
distribution pattern of a Sall1 fragment containing aa 2–435 in
COS-1 cells has been reported [8]. Whether these deviating
observations reflect differences of NIH-3T3 and COS-1 cells –
e.g., with respect to endogenous Sall1 expression and subsequent
intranuclear heterodimerization with exogenous Sall1 fragments
at heterochromatic sites – is presently unclear. There is no
detectable Sall1 expression in NIH-3T3 cells [10], but to our
knowledge, this has not been tested for COS-1 cells so far.
3.4. Conclusions
In summary, we have provided strong evidence that human
SALL1 is a potent transcriptional repressor and report that it
contains two repression domains, one at the extreme N-
terminus and one in the central region of the protein.
Repression by the central domain was associated with
heterochromatin localization.
The presence of multiple independent repression domains
has been demonstrated for other transcription factors, e.g. for
Brinker, Hesx1, and ZEB [26–28]. In some cases the two
domains recruit different co-repressors to mediate transcrip-
tional repression and can function independently or coopera-
tively. Remarkably, another C2H2 type zinc finger protein,
Ikaros, colocalizes to centromeric foci with inactive, develop-
mentally-regulated genes, suggesting that it may contribute to
the pericentromeric repositioning and heritable inactivation of
these genes [29,30]. Identification of in vivo target genes
regulated by SALL1 will be important to investigate whether a
similar model can be applied here and to analyze the repression
mechanisms used by SALL1 in detail.
The findings presented in this study may have important
implications for the pathogenesis of TBS. The majority of
SALL1 mutations occur 5′ to the region encoding the first
double zinc finger domain [31,32], and all known SALL1
mutations cause premature stop codons. New results [33]
document that deletions of the entire SALL1 gene also lead to
TBS, confirming that SALL1 haploinsufficiency plays a role in
the etiology of the disorder. Alleles resulting from mutations in
the 5′ region of exon 2 encode for truncated proteins with strong
repressor activity but without the central repression and
heterochromatin localization domain. Despite of their potential
to act as strong transcriptional repressors, these proteins will
probably not localize to the physiological site of action, i.e. the
heterochromatic foci. In addition, the truncated proteins are
present in both the nucleus and cytoplasm in the TBS mouse
model [5] and in the chick as shown by tissue culture
experiments [9]. Furthermore, in the latter case, the truncated
proteins bind other SAL proteins and move them from the
nucleus to the cytoplasm. Mutations further 3′ in the SALL1
gene are thought to result mostly in milder phenotypes than the
5′ mutations [32,34]. If some of those mutations lead to
truncated proteins including both repression domains and, more
importantly, the heterochromatin localization domain, these
proteins could have some residual function which might explain
the milder phenotype.The observation that the human TBS phenotype can result
from a SALL1 dosage effect [33] raises the possibility that the
critical point in the pathogenesis is the correct dosage of
functional SALL1 protein at the heterochromatic foci. A
deletion of one allele results in a 50% reduction of this dosage.
A 5′ truncating mutation leads to a truncated protein, which does
not reach its site of action and in addition probably even removes
some full length protein of the normal allele from the nucleus.
Therefore, the in most instances more severe phenotype of the 5′
truncating mutations might result from a reduction of the
functional protein at the site of action by more than 50%.
However, some riddles still remain to be solved: The
interaction between truncated SALL1 and functional SALL1 or
other SALL proteins and the relocalization of the functional
proteins requires the presence of the evolutionary conserved
glutamine-rich region in the amino terminal part of the truncated
protein [9]. The identification of the TBS-causing SALL1
mutation c.419delC [3], which would result in a truncated
protein lacking the interaction domain, shows that this theory
does not fully explain the etiology. Further work on the function
of SALL1 and its involvement in various signaling pathways
(e.g., Wnt signaling pathway) is required to unravel TBS
pathogenesis.
Acknowledgements
The authors would like to thank Wolfgang Engel for his
support. This study was funded by the Fritz-Thyssen-Stiftung
(grant no. 2000 1071 to S.K.B. and J.K.). C.N. was supported
by the DFG (Deutsche Forschungsgemeinschaft) and the
BONFOR program of the Medical Faculty, Rheinische
Friedrich-Wilhelms-University, Bonn.
References
[1] J. Kohlhase, A. Wischermann, H. Reichenbach, U. Froster, W. Engel,
Mutations in the SALL1 putative transcription factor gene cause Townes–
Brocks syndrome, Nat. Genet. 18 (1998) 81–83.
[2] C.M. Powell, R.C. Michaelis, Townes–Brocks syndrome, J. Med. Genet.
36 (1999) 89–93.
[3] J. Kohlhase, P. Taschner, P. Burfeind, B. Pasche, B. Newman, C. Blanck,
M. Breuning, L. ten Kate, P. Maaswinkel-Mooy, B. Mitulla, J. Seidel, S.
Kirkpatrick, R. Pauli, D. Wargowski, K. Devriendt, W. Proesmans, O.
Gabrielli, G. Coppa, E. Wesby-van Swaay, R. Trembath, A. Schinzel, W.
Reardon, E. Seemanova, W. Engel, Molecular analysis of SALL1
mutations in Townes–Brocks syndrome, Am. J. Hum. Genet. 64 (1999)
435–445.
[4] R. Nishinakamura, Y. Matsumoto, K. Nakao, K. Nakamura, A. Sato, N.
Copeland, D. Gilbert, N. Jenkins, S. Scully, D. Lacey, M. Katsuki, M.
Asashima, T. Yokota, Murine homolog of SALL1 is essential for ureteric
bud invasion in kidney development, Development 128 (2001)
3105–3115.
[5] S.M. Kiefer, K.K. Ohlemiller, J. Yang, B.W. McDill, J. Kohlhase, M.
Rauchman, Expression of a truncated Sall1 transcriptional repressor is
responsible for Townes–Brocks syndrome birth defects, Hum. Mol. Genet.
12 (2003) 2221–2227.
[6] C. Netzer, L. Rieger, A. Brero, C.-D. Zhang, M. Hinzke, J. Kohlhase, S.K.
Bohlander, SALL1, the gene mutated in Townes–Brocks syndrome,
encodes a transcriptional repressor which interacts with TRF1/ PIN2 and
localizes to pericentromeric heterochromatin, Hum. Mol. Genet. 10 (2001)
3017–3024.
391C. Netzer et al. / Biochimica et Biophysica Acta 1762 (2006) 386–391[7] C. Netzer, S. Bohlander, L. Rieger, S. Muller, J. Kohlhase, Interaction of
the developmental regulator SALL1 with UBE2I and SUMO-1, Biochem.
Biophys. Res. Commun. 296 (2002) 870–876.
[8] S. McLeskey Kiefer, B. McDill, J. Yang, M. Rauchman, Murine Sall1
represses transcription by recruiting a histone deacetylase complex, J. Biol.
Chem. 277 (2002) 14869–14876.
[9] D. Sweetman, T. Smith, E.R. Farrell, A. Chantry, A. Münsterberg, The
conserved glutamine rich region of chick csal1 and csal3 mediates protein
interactions with other spalt family members. Implications for Townes–
Brocks syndrome, J. Biol. Chem. 278 (2003) 6560–6566.
[10] A. Sato, S. Kishida, T. Tanaka, A. Kikuchi, T. Kodama, M. Asashima, R.
Nishinakamura, Sall1, a causative gene for Townes–Brocks syndrome,
enhances the canonical Wnt signaling by localizing to heterochromatin,
Biochem. Biophys. Res. Commun. 19 (2004) 103–113.
[11] E.R. Farrell, A.E. Munsterberg, csal1 is controlled by a combination of
FGF and Wnt signals in developing limb buds, Dev. Biol. 225 (2000)
447–458.
[12] D. Li, Y. Tian, Y. Ma, T. Benjamin, p150(Sal2) is a p53-independent
regulator of p21(WAF1/CIP), Mol. Cell. Biol. 24 (2004) 3885–3893.
[13] J. Kohlhase, Isolierung und Charakterisierung einer humanen Genfamilie
mit Ähnlichkeit zu spalt, einem regionsspezifischen homöotischen Gen
von Drosophila melanogaster, Doctoral Thesis, University of Göttingen,
Göttingen, 1996.
[14] G. Schlüter, D. Boinska, S.C. Nieman-Seyde, Evidence for
translational repression of the SOCS-1 major open reading frame by
an upstream open reading frame, Biochem. Biophys. Res. Commun.
268 (2000) 255–261.
[15] T. Hollemann, R. Schuh, T. Pieler, R. Stick, Xenopus Xsal-1, a vertebrate
homolog of the region specific homeotic gene spalt of Drosophila, Mech.
Dev. 55 (1996) 19–32.
[16] T. Ott, K.H. Kaestner, A.P. Monaghan, G. Schütz, The mouse homolog of
the region specific homeotic gene spalt of Drosophila is expressed in the
developing nervous system and in mesoderm-derived structures, Mech.
Dev. 56 (1996) 117–128.
[17] J. Kohlhase, R. Schuh, G. Dowe, R.P. Kühnlein, H. Jäckle, B. Schroeder,
W. Schulz-Schaeffer, H.A. Kretzschmar, A. Köhler, U. Müller, M. Raab-
Vetter, E. Burkhardt, W. Engel, R. Stick, Isolation, characterization, and
organ-specific expression of two novel human zinc finger genes related to
the Drosophila gene spalt, Genomics 38 (1996) 291–298.
[18] R. Köster, R. Stick, F. Loosli, J. Wittbrodt, Medaka spalt acts as a target
gene of hedgehog signaling, Development 124 (1997) 3147–3156.
[19] E.R. Farrell, A.E. Munsterberg, csal1 is controlled by a combination of
FGF and Wnt signals in developing limb buds, Dev. Biol. 225 (2000)
447–458.
[20] E.R. Farrell, G. Tosh, E. Church, A.E. Munsterberg, Cloning and
expression of CSAL2, a new member of the spalt gene family in chick,
Mech. Dev. 102 (2001) 227–230.[21] Y. Onuma, R. Nishinakamura, S. Takahashi, T. Yokota, M. Asashima,
Molecular cloning of a novel Xenopus spalt gene (Xsal-3), Biochem.
Biophys. Res. Commun. 264 (1999) 151–156.
[22] J. Kohlhase, S. Hausmann, G. Stojmenovic, C. Dixkens, K. Bink, W.
Schulz-Schaeffer, M. Altmann, W. Engel, SALL3, a new member of the
human spalt-like gene family, maps to 18q23. Genomics 62 (1999)
216–222.
[23] J. Kohlhase, M. Altmann, L. Archangelo, C. Dixkens, W. Engel, Genomic
cloning, chromosomal mapping, and expression analysis of Msal-2,
Mamm. Genome 11 (2000) 64–68.
[24] J. Kohlhase, M. Heinrich, L. Schubert, M. Liebers, A. Kispert, F. Laccone,
P. Turnpenny, R.M. Winter, W. Reardon, Okihiro syndrome is caused by
SALL4 mutations, Hum. Mol. Genet. 11 (2002) 2979–2987.
[25] J.H. Laity, B.M. Lee, P.E. Wright, Zinc finger proteins: new insights into
structural and functional diversity, Curr. Opin. Struct. Biol. 11 (2001)
39–46.
[26] A.A. Postigo, D.C. Dean, Independent repressor domains in ZEB regulate
muscle and T-cell differentiation, Mol. Cell. Biol. 19 (1999) 7961–7971.
[27] J.S. Dasen, J.P. Barbera, T.S. Herman, S.O. Connell, L. Olson, B. Ju, J.
Tollkuhn, S.H. Baek, D.W. Rose, M.G. Rosenfeld, Temporal regulation of
a paired-like homeodomain repressor/TLE corepressor complex and a
related activator is required for pituitary organogenesis, Genes Dev. 15
(2001) 3193–3207.
[28] P. Hasson, B. Muller, K. Basler, Z. Paroush, Brinker requires two
corepressors for maximal and versatile repression in Dpp signalling,
EMBO J. 20 (2001) 5725–5736.
[29] K.E. Brown, S.S. Guest, S.T. Smale, K. Hahm, M. Merkenschlager, A.G.
Fisher, Association of transcriptionally silent genes with Ikaros complexes
at centromeric heterochromatin, Cell 91 (1997) 845–854.
[30] B.S. Cobb, S. Morales-Alcelay, G. Kleiger, K.E. Brown, A.G. Fisher, S.T.
Smale, Targeting of Ikaros to pericentromeric heterochromatin by direct
DNA binding, Genes Dev. 14 (2000) 2146–2160.
[31] J. Kohlhase, SALL1 mutations in Townes–Brocks syndrome and related
disorders, Hum. Mut. 16 (2000) 460–466.
[32] E.M. Botzenhart, A. Green, H. Ilyina, R. König, R.B. Lowry, I.F.M. Lo, M.
Shohat, L.W. Burke, J. McGaughran, R. Chafai, G. Pierquin, R.C.
Michaelis, M.L. Whiteford, K.O.J. Simola, J. Kohlhase, SALL1 mutation
analysis in Townes–Brocks syndrome: 12 novel mutations and expansion
of the phenotype, Hum. Mut. 26 (2005) 282.
[33] W. Borozdin, K. Steinmann, B. Albrecht, A. Bottani, K. Devriendt, M.
Leipoldt, J. Kohlhase, Detection of heterozygous SALL1 deletions by
quantitative real time PCR proves the contribution of a SALL1 dosage effect
in the pathogenesis of Townes–Brocks syndrome. Hum. Mut. (in press).
[34] C. Blanck, J. Kohlhase, S. Engels, P. Burfeind, A. Bottani, W. Engel, H.Y.
Kroes, J.M. Cobben, Three novel SALL1 mutations extend the mutational
spectrum in Townes–Brocks syndrome, J. Med. Genet. 37 (2000)
303–307.
